Project Grant R01CA299011
Award Date 9/23/25
Completion Date 8/31/29
Dollars Obligated $2.1M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Illinois, USA
Similar Awards
- This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides $661,072 to Northwestern University to develop a novel, first-in-class small molecule inhibitor that targets the USP22 oncogene. The goal is to create a therapy with dual immuno-activating and cancer-targeting efficacy to treat triple negative breast cancer. The research, conducted in partnership with startup company Exomira Medicine Inc., aims to advance the therapeutic...
- The University of Chicago received a $372,628 Project Grant from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) on September 12, 2025. The grant funds the development of a large-format spatial transcriptomics profiling platform, called Array-Seq, to enable detailed spatiomolecular analysis of human cancer samples. This technology aims to overcome limitations of existing spatial transcriptomics methods by increasing throughput, sample size compatibility, and...
- This federal Project Grant award of $205,700 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research at the Sloan-Kettering Institute for Cancer Research in New York aimed at understanding and overcoming rapid resistance to targeted therapies in colorectal cancer. The key objectives are to evaluate how intrinsic tumor features modulate the development of resistance to targeted therapies, and to test a novel combination approach to...
- This federal Project Grant award of $584,521 was provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The Leland Stanford Junior University (Stanford University) on August 8, 2025. The grant supports a research study to understand the non-genetic mechanisms that enable subclonal tumor populations to survive radiotherapy for soft tissue sarcomas. The key objectives are to: 1) identify and validate epigenetic changes that cause subclonal radioresistance, 2) define...
- The National Cancer Institute, under the Cancer Treatment Research federal grant program (CFDA 93.395), awarded a $400,000 project grant to Nuago Therapeutics Inc. on June 9, 2025. The grant supports the development of a short RNA therapeutic to treat ovarian cancer. This research aims to develop a novel, targeted cancer therapy that can potentially overcome limitations of existing cancer treatments. The award has a projected completion date of May 31, 2026 and will be conducted at the company's...
- This $149,394 Project Grant was awarded on August 1, 2025 by the National Cancer Institute (NCI), part of the Department of Health and Human Services, under the federal Cancer Detection and Diagnosis Research program (CFDA 93.394). The grant supports research led by the University of California, Davis to advance the development of targeted radiopharmaceuticals for cancer diagnosis and therapy. Specifically, the research focuses on designing, synthesizing, and optimizing novel molecular imaging...
- This $732,000 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, will support research under the Cancer Treatment Research program. The grant recipient, Northwestern University, will develop a bridge-lipid nanoparticle platform to reprogram immunosuppressive tumor-associated myeloid cells and potentiate radiotherapy for glioblastoma. Over a five-year period, the university will conduct three aims: harnessing myeloid cells to phagocytose...
- This federal Project Grant award of $545,078, funded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), is supporting research at The Johns Hopkins University to investigate the use of radiopharmaceutical therapy in combination with inhibition of glutamine metabolism as a novel therapeutic strategy for prostate cancer and renal cell carcinoma. The project aims to systematically evaluate the effect of prostate-specific membrane antigen (PSMA)-based radiopharmaceutical...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the University of Rochester provides $639,098 to develop an innovative treatment for metastatic pancreatic cancer. The research aims to overcome both intrinsic and extrinsic barriers to treatment efficacy, specifically by targeting the tumor microenvironment through a combination of local radiotherapy and intratumoral immunotherapy using a novel mRNA-based nanoparticle delivery system. The...
- The federal Project Grant award of $160,330 from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) is supporting research by the University of Illinois to investigate the biochemical determinants of genome instability induced by eukaryotic topoisomerase II. The project aims to determine how the biochemical properties of topoisomerases, along with factors like chromatin structure and DNA repair pathways, influence genome instability. This research builds on the...